Literature DB >> 10644899

Acute effects of estradiol pretreatment on the response to d-amphetamine in women.

A J Justice1, H de Wit.   

Abstract

Little is known about the interactions between ovarian hormones and responses to psychoactive drugs in humans. Preclinical studies suggest that ovarian hormones such as estrogen and progesterone have direct and indirect central nervous system actions and that these hormones can influence behavioral responses to psychoactive drugs. In the present study, we assessed the subjective and physiological effects of d-amphetamine (AMPH; 10 mg p.o.) after pretreatment with estradiol. Two groups of healthy, regularly cycling women participated in two sessions scheduled during the early follicular phases of two menstrual cycles. One group received estradiol patches (Estraderm TTS; 0.8 mg) which elevated plasma estradiol levels to approximately 750 pg/ml on both sessions; the other group received placebo patches on both sessions. Both groups received AMPH (10.0 mg) and placebo in a randomized and counterbalanced order on the two sessions. Dependent measures included self-report questionnaires, physiological measures, and plasma hormone levels. Most of the subjective and physiological effects of AMPH were not affected by acute estradiol treatment. Nevertheless, estradiol pretreatment increased the magnitude of the effects of AMPH on subjective ratings of 'pleasant stimulation' and decreased ratings of 'want more'. Also, estradiol produced some subjective effects when administered alone: It increased subjective ratings of 'feel drug', 'energy and intellectual efficiency', and 'pleasant stimulation'. These results provide limited evidence that the stimulating effects of AMPH are increased by acute estradiol pretreatment. Copyright 2000 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10644899     DOI: 10.1159/000054520

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  34 in total

1.  How reward and emotional stimuli induce different reactions across the menstrual cycle.

Authors:  Michiko Sakaki; Mara Mather
Journal:  Soc Personal Psychol Compass       Date:  2012-01-01

Review 2.  Neural mechanisms of reproduction in females as a predisposing factor for drug addiction.

Authors:  Valerie L Hedges; Nancy A Staffend; Robert L Meisel
Journal:  Front Neuroendocrinol       Date:  2010-02-19       Impact factor: 8.606

Review 3.  Sex differences in drug abuse.

Authors:  Jill B Becker; Ming Hu
Journal:  Front Neuroendocrinol       Date:  2007-08-24       Impact factor: 8.606

4.  Sex differences in drug-related stress-system changes: implications for treatment in substance-abusing women.

Authors:  Helen C Fox; Rajita Sinha
Journal:  Harv Rev Psychiatry       Date:  2009       Impact factor: 3.732

Review 5.  CRF modulation of central monoaminergic function: Implications for sex differences in alcohol drinking and anxiety.

Authors:  Kristen E Pleil; Mary Jane Skelly
Journal:  Alcohol       Date:  2018-02-02       Impact factor: 2.405

6.  Progesterone improves cognitive performance and attenuates smoking urges in abstinent smokers.

Authors:  Mehmet Sofuoglu; Maria Mouratidis; Marc Mooney
Journal:  Psychoneuroendocrinology       Date:  2010-08-02       Impact factor: 4.905

7.  Gender, brain-derived neurotrophic factor Val66Met, and frequency of methamphetamine use.

Authors:  Keith G Heinzerling; Steven Shoptaw
Journal:  Gend Med       Date:  2012-03-23

8.  Impact of pubertal and adult estradiol treatments on cocaine self-administration.

Authors:  Adam N Perry; Christel Westenbroek; Jill B Becker
Journal:  Horm Behav       Date:  2013-09-05       Impact factor: 3.587

Review 9.  Sexual differentiation of motivation: a novel mechanism?

Authors:  Jill B Becker
Journal:  Horm Behav       Date:  2009-05       Impact factor: 3.587

10.  Nongenomic mechanisms of physiological estrogen-mediated dopamine efflux.

Authors:  Rebecca A Alyea; Cheryl S Watson
Journal:  BMC Neurosci       Date:  2009-06-16       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.